CN104592091B - 一种含吲哚乙酸核心结构的化合物及其应用 - Google Patents

一种含吲哚乙酸核心结构的化合物及其应用 Download PDF

Info

Publication number
CN104592091B
CN104592091B CN201510040470.5A CN201510040470A CN104592091B CN 104592091 B CN104592091 B CN 104592091B CN 201510040470 A CN201510040470 A CN 201510040470A CN 104592091 B CN104592091 B CN 104592091B
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510040470.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104592091A (zh
Inventor
冉瑞琼
邓廉夫
李玉明
周欣
李瀚旻
王海勇
唐国涛
赵子淏
王健生
袁定清
王建华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing An Jianxi Medical Science And Technology Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510040470.5A priority Critical patent/CN104592091B/zh
Publication of CN104592091A publication Critical patent/CN104592091A/zh
Priority to EP16742705.3A priority patent/EP3252039B1/en
Priority to US15/547,013 priority patent/US10494341B2/en
Priority to AU2016212552A priority patent/AU2016212552B2/en
Priority to PCT/CN2016/071934 priority patent/WO2016119643A1/zh
Priority to EP21203847.5A priority patent/EP3978473A1/en
Priority to JP2017540779A priority patent/JP6442615B2/ja
Priority to KR1020177021530A priority patent/KR101975299B1/ko
Application granted granted Critical
Publication of CN104592091B publication Critical patent/CN104592091B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201510040470.5A 2015-01-27 2015-01-27 一种含吲哚乙酸核心结构的化合物及其应用 Active CN104592091B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201510040470.5A CN104592091B (zh) 2015-01-27 2015-01-27 一种含吲哚乙酸核心结构的化合物及其应用
PCT/CN2016/071934 WO2016119643A1 (zh) 2015-01-27 2016-01-25 一种含吲哚乙酸核心结构的化合物及其应用
US15/547,013 US10494341B2 (en) 2015-01-27 2016-01-25 Compound containing indoleacetic acid core structure and use thereof
AU2016212552A AU2016212552B2 (en) 2015-01-27 2016-01-25 Compound containing indoleacetic acid core structure and use thereof
EP16742705.3A EP3252039B1 (en) 2015-01-27 2016-01-25 Compound containing indoleacetic acid core structure and use thereof
EP21203847.5A EP3978473A1 (en) 2015-01-27 2016-01-25 Compound containing an indoleacetic acid core structure and use thereof
JP2017540779A JP6442615B2 (ja) 2015-01-27 2016-01-25 インドール酢酸コア構造を含む化合物とその応用
KR1020177021530A KR101975299B1 (ko) 2015-01-27 2016-01-25 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510040470.5A CN104592091B (zh) 2015-01-27 2015-01-27 一种含吲哚乙酸核心结构的化合物及其应用

Publications (2)

Publication Number Publication Date
CN104592091A CN104592091A (zh) 2015-05-06
CN104592091B true CN104592091B (zh) 2017-07-04

Family

ID=53118197

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510040470.5A Active CN104592091B (zh) 2015-01-27 2015-01-27 一种含吲哚乙酸核心结构的化合物及其应用

Country Status (7)

Country Link
US (1) US10494341B2 (enExample)
EP (2) EP3978473A1 (enExample)
JP (1) JP6442615B2 (enExample)
KR (1) KR101975299B1 (enExample)
CN (1) CN104592091B (enExample)
AU (1) AU2016212552B2 (enExample)
WO (1) WO2016119643A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592091B (zh) 2015-01-27 2017-07-04 冉瑞琼 一种含吲哚乙酸核心结构的化合物及其应用
CN109180521B (zh) * 2018-09-05 2021-08-31 中国人民解放军陆军军医大学 一种抗肿瘤化合物及其制备方法、用途
US12186332B2 (en) * 2019-06-27 2025-01-07 Stowers Institute For Medical Research Methods for overcoming WNT/beta-catenin anti-cancer resistance in leukemia stem cells
EP4417599A4 (en) * 2021-10-15 2025-11-19 Beijing Anjianxi Bio Medical Tech Co Ltd ALKYL ALCOHOL DERIVATIVE 2,3-DIMETHOXY-5-METHYL-1,4-BENZOQUINONE AND ITS USES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654349A (en) * 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
CN1237162A (zh) * 1996-11-12 1999-12-01 美国家用产品公司 Cox－2的茚抑制剂
WO2006099416A1 (en) * 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
WO2014138922A1 (en) * 2013-03-15 2014-09-18 Indanio Bioscience Inc. Uses for idebenone and related benzoouinones in ppar-related diseases and conditions
CN104592091B (zh) * 2015-01-27 2017-07-04 冉瑞琼 一种含吲哚乙酸核心结构的化合物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654349A (en) * 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
CN1237162A (zh) * 1996-11-12 1999-12-01 美国家用产品公司 Cox－2的茚抑制剂
WO2006099416A1 (en) * 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use

Also Published As

Publication number Publication date
JP2018505184A (ja) 2018-02-22
US10494341B2 (en) 2019-12-03
CN104592091A (zh) 2015-05-06
EP3252039A4 (en) 2018-07-25
KR20170129688A (ko) 2017-11-27
WO2016119643A1 (zh) 2016-08-04
EP3252039A1 (en) 2017-12-06
AU2016212552B2 (en) 2018-10-25
AU2016212552A1 (en) 2017-08-17
KR101975299B1 (ko) 2019-05-07
EP3252039B1 (en) 2021-11-03
JP6442615B2 (ja) 2018-12-19
EP3978473A1 (en) 2022-04-06
US20180022700A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
Rettondin et al. Gold (III) complexes with ONS-Tridentate thiosemicarbazones: Toward selective trypanocidal drugs
CN104592091B (zh) 一种含吲哚乙酸核心结构的化合物及其应用
CN103275051B (zh) 一种7,3’,4’-三羟基黄酮衍生物及其在制备治疗肝癌药物中的应用
CN110256313A (zh) 一种光敏剂前药化合物及其制备方法和应用
CN101993370A (zh) 蓝萼甲素酸酯衍生物及其制备方法和应用
CN111349092A (zh) 一种线粒体靶向化合物及其制备方法和应用
CN102627685A (zh) 一氧化氮供体型谷胱甘肽类化合物、其制备方法及医药用途
Shao et al. Design of a prodrug photocage for cancer cells detection and anticancer drug release
CN102746346A (zh) 以碳原子为连接点的富勒烯单糖衍生物及其制备方法
CN101402667A (zh) 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途
CN113461563A (zh) Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用
JP6404220B2 (ja) テアニン誘導体とカルボン酸クマリン誘導体との縮合生成物、その中間体、調製方法、及びその使用
CN107793410B (zh) 苯并硒二唑的衍生物及其应用
CN117756859A (zh) 一种α-TOS修饰的环金属铱（III）配合物及其合成方法和应用
CN104987356A (zh) 一种熊果酸-糖酵解抑制剂dca偶联物及其应用
CN111057063B (zh) 一种用于急性淋巴细胞白血病的靶向光动力治疗的酞菁衍生物及其制备方法
RO129522A0 (ro) Agenţi antitumorali derivaţi ai n-()-1-metil-1h-pirazol-4-carboxamidei
CN112358492A (zh) 碳硼烷基塞来昔布及其制备和在头颈癌硼中子俘获治疗药物中的应用
CN108030777A (zh) 氯胍在制备抗肿瘤药物中的应用
CN102504013B (zh) 一种靶向抗癌转移化学药物padm及制备方法和用途
CN105646493B (zh) 一种用于预防和治疗器官损伤的化合物及其制备方法和用途
Li et al. Copper (II) Complexes of Pyrazino [2, 3‐F][1, 10] Phenanthroline Induce Cuprotosis and Immunogenic Cell Death in Triple‐Negative Breast Cancer
CN119039265B (zh) 一种甲基哌嗪-查尔酮类衍生物及其制备方法和应用以及药物制剂
CN102000061B (zh) 硝基苯甲酰水飞蓟宾用于制备糖苷酶抑制剂的药物用途
CN115057798A (zh) 荧光探针、其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20161024

Address after: 430075 No. 666, hi tech Avenue, East Lake Development Zone, Hubei, Wuhan

Applicant after: Ran Ruiqiong

Applicant after: Xu Yao

Address before: 430075 No. 666, hi tech Avenue, East Lake Development Zone, Hubei, Wuhan

Applicant before: Ran Ruiqiong

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20171108

Address after: 100036 Beijing city Haidian District Cuiwei Road No. 2 on Printing No. 5 X301

Patentee after: Beijing An Jianxi medical science and Technology Co., Ltd.

Address before: 430075 No. 666, hi tech Avenue, East Lake Development Zone, Hubei, Wuhan

Co-patentee before: Xu Yao

Patentee before: Ran Ruiqiong

TR01 Transfer of patent right